Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results

First Full Year of Profitability with GAAP Earnings Per Share of $0.03; 2008 Nexavar Net Sales of $678 Million Represents 82% Growth Over 2007

Emeryville, CA — Feb. 23, 2009

Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its financial results for the full year and fourth quarter 2008. For the full year, Onyx recorded net income of $1.9 million, or $0.03 per diluted share, compared with a net loss of $34.2 million, or $0.67 per diluted share, for the same period in 2007. Excluding employee stock-based compensation expense, non-GAAP net income for the full year 2008 was $20.7 million, or $0.37 per diluted share, compared to a non-GAAP net loss of $20.0 million, or $0.39 per diluted share, for the same period in 2007. Onyx reported a net loss of $30.2 million, or $0.53 per diluted share, for the fourth quarter 2008, compared to a net loss of $11.7 million, or $0.21 per diluted share, in the same period in 2007. Excluding employee stock-based compensation expense, non-GAAP net loss for the fourth quarter 2008 was $25.2 million, or $0.45 per diluted share, compared to a non-GAAP net loss of $7.8 million, or $0.14 per diluted share, for the same period in 2007. A description of the non-GAAP calculations and reconciliation to comparable GAAP measures are provided below in the accompanying Reconciliation of GAAP to Non-GAAP Net Income.

Global Nexavar net sales grew 82% to $677.8 million for the full year 2008, and grew 41% to $176.5 million for the fourth quarter 2008, compared to $371.7 million and $124.9 million in the same periods in 2007. Onyx, with its collaborator, Bayer HealthCare Pharmaceuticals, Inc., or Bayer, is marketing and developing Nexavar® (sorafenib) tablets, an anticancer therapy currently approved for the treatment of liver cancer and advanced kidney cancer in the U.S., European Union and other territories. In accordance with Onyx’s collaboration agreement with Bayer, Bayer recognizes all revenue from the sale of Nexavar.

“This has been a year of remarkable growth and advancement for Onyx, as we increased year-over-year sales by 82% and achieved profitability for the year. We’ve leveraged our successes to invest strategically in the long-term growth potential of the company, creating a rich pipeline with Nexavar and beginning to shape a diversified portfolio beyond Nexavar through strategic but disciplined corporate development activities,” stated N. Anthony Coles, M.D., president and chief executive officer of Onyx. “With continued sales growth from Nexavar, a comprehensive development program with near-term value drivers, and a strong financial position, we believe we are well-positioned to drive growing shareholder value in 2009 and the years to come.”

Revenue from Collaboration Agreement
As of December 31, 2021 and for earlier periods presented, Onyx has adopted a new financial statement presentation based on guidance from the Financial Accounting Standards Board’s Emerging Issues Task Force (EITF) 07-1, Accounting for Collaborative Arrangements. This new presentation changes the classification of amounts included in specific lines in the Statement of Operations, but does not change net income (loss) or net income (loss) per share.

Under this new presentation, the Statement of Operations includes the line item “Revenue from Collaboration Agreement.” This line item consists of Onyx’s share of the commercial profit generated from the collaboration with Bayer, reimbursement of Onyx’s shared marketing costs related to Nexavar and Nexavar royalty revenue. Onyx’s 50% share of collaboration research and development expenses is included in the research and development expense line item.

For the full year and fourth quarter 2008, Onyx reported revenue from collaboration agreement of $194.3 million and $49.7 million, respectively, compared to $90.4 million and $26.1 million for the same periods in 2007. The increase in revenue from collaboration agreement between periods is due to an increase in Nexavar revenue recognized by Bayer and higher royalty revenue, partially offset by an increase in commercial expenses related to Nexavar.

Operating Expenses
Onyx recorded research and development expenses of $123.7 million in the full year 2008 and $59.9 million in the fourth quarter 2008, compared to $83.3 million and $27.2 million for the same periods in 2007. Research and development expenses in fourth quarter 2008 include payments made by Onyx to S*BIO Pte Ltd under a development collaboration, option and license agreement and to BTG International Limited under a development and license agreement. Research and development expenses included $3.2 million and $1.1 million of employee stock-based compensation for the full year and fourth quarter 2008, respectively.

Selling, general and administrative expenses were $81.0 million in the full year 2008 and $22.0 million in the fourth quarter 2008, compared to $60.5 million and $16.4 million for the same periods in 2007. Higher selling, general and administrative expenses were primarily due to increased marketing spend and employee-related expenses to support Nexavar, as well as, increased headcount and employee-related expenses to support Onyx’s growth. Selling, general and administrative expenses included $15.6 million and $3.9 million of employee stock-based compensation for the full year and fourth quarter 2008, respectively.

Cash, Cash Equivalents and Marketable Securities
At December 31, 2008, cash, cash equivalents, and current and noncurrent marketable securities were $458.0 million, compared to $469.7 million at December 31, 2007. This decrease was primarily due to payments made under our agreements with S*BIO and BTG, partially offset by positive cash flow from operations.

Management Conference Call Today
Onyx will host a teleconference and webcast to provide a general business overview and discuss financial results. The event will begin at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on February 23, 2009. The live webcast will be available at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-413-3238 and using the passcode 23828951. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 23828951 later in the day. The replay will be available through March 23, 2009.

About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treatedTM. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer and other cancers. For more information about Onyx, visit http://www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals Inc.

This news release contains “forward-looking statements” of Onyx within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements regarding sales trends and commercial activities and the timing, progress and results of clinical development, regulatory filings and actions. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx’s Annual Report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission, under the heading “Risk Factors” for a more detailed description of such factors, as well as the company’s subsequent quarterly reports on Form 10 Q. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

View Financials

Return to 2009 Press Releases